Client Portal
Spherix Global InsightsSpherix Global Insights
Menu

Expertise

  • Dermatology
  • Gastroenterology
  • Nephrology
  • Neurology
  • Rheumatology

Spherix

  • Services
  • About
  • Media
  • Connect

Publication Plan

  • Join Our Team
  • Privacy Policy
  • Client Portal
Spherix Global Insights

Back to All Media

Nephrology

April 07, 2021

COVID-19DermatologyGastroenterologyNephrologyNeurologyPress ReleaseRheumatology

Specialty Physicians Point to Permanent Changes Introduced by the COVID-19 Pandemic, Highlighting the Challenges that Lie Ahead for Pharmaceutical Manufacturers

Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...

March 22, 2021

NephrologyPress Release

Groundbreaking New Research from Spherix Global Insights Leverages More Than 1,100 Patient Charts to Provide Insights on IgA Nephropathy, Focal Segmental Glomerulosclerosis, and Alport Syndrome

Spherix announces the release of three new research publications in its RealWorld Dynamix™ series, revealing patient types, treatment paradigms, and...

March 12, 2021

NephrologyPress ReleaseRheumatology

On the Heels of Recent FDA Approvals, GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin) Emerge as Practical and Effective Tools in the Treatment of Lupus Nephritis

According to Spherix Global Insights, nephrologists and rheumatologists express measured optimism about these treatment options and seek more experience with...

March 04, 2021

NephrologyPress Release

As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve – If at All?

According to new research published by Spherix Global Insights, the CKD non-dialysis market is poised for seismic shifts as SGLT2...

February 12, 2021

COVID-19DermatologyGastroenterologyNephrologyNeurologyRheumatology

The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era

According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...

January 29, 2021

DermatologyGastroenterologyNephrologyNeurologyPress ReleaseRheumatology

Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets

The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...

January 25, 2021

NephrologyPress Release

Unmet Need in Lupus Nephritis Finally Addressed with New FDA Approvals for GlaxoSmithKline’s BENLYSTA (belimumab) and Aurinia Pharmaceuticals’ LUPKYNIS (voclosporin)

According to Spherix Global Insights, rheumatologists and nephrologists are excited about new treatment options in addition to a multitude of...

November 02, 2020

NephrologyPress Release

Nephrologists Attending the American Society of Nephrology Virtual Meeting Point to New Data on the SGLT2 Inhibitor Class as Being the Most Compelling Presented at the Conference

According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during...

September 30, 2020

NephrologyPress ReleaseRheumatology

Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights

Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from...

September 15, 2020

COVID-19DermatologyGastroenterologyNephrologyNeurologyPress ReleaseRheumatology

Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies

Though surveyed US specialists report shrinking trepidation prescribing certain drugs amid the COVID-19 pandemic, hesitation to prescribe new brands remains...

September 08, 2020

NephrologyPress Release

SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights

The SGLT2 inhibitor class, specifically Janssen’s Invokana (promoted by Relypsa in nephrology), is gaining momentum with nephrologists as potential DKD...

August 31, 2020

NephrologyPress Release

Nephrologists Point to Profound Unmet Need for New Agents to Treat Glomerular Diseases Such as IgA Nephropathy, Focal Segmental Glomerulosclerosis (FSGS), and Lupus Nephritis

According to Spherix Global Insights, nephrologists anxiously await pipeline products such as Retrophin’s sparsentan, Aurinia’s voclosporin, Reata’s bardoxolone methyl, and...

1 2 3 … 5 Next »
Spherix Global Insights
  • Expertise
    • Dermatology
    • Gastroenterology
    • Nephrology
    • Neurology
    • Rheumatology
  • Services
  • About
  • Connect
  • Media Center
Spherix Global Insights

Privacy Policy

Impact of COVID-19
Special Topix™: Multi-Specialty Impact of COVID-19 (US)

An ongoing series of monthly monitoring that evaluates the impact of COVID-19 on physicians and their practices – including, but not limited to, the utilization of telemedicine, at-risk patient groups, key concerns, support from industry, and future changes in prescribing patterns. Specialty reports are available for dermatology, gastroenterology, nephrology, neurology, and rheumatology.

Learn more about this service